Cargando…
FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA)
Disclosure: D. van Rooyen: None. R. Scheske: None. A.M. Lerario: None. W.E. Rainey: None. R.J. Auchus: None. G.D. Hammer: None. T. Else: None. Background: Adrenal tumors are very common, with the vast majority being benign adrenocortical adenomas (ACA). Adrenocortical carcinomas (ACC) represent only...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554608/ http://dx.doi.org/10.1210/jendso/bvad114.187 |
_version_ | 1785116452811964416 |
---|---|
author | van Rooyen, Desmaré Scheske, Rachel Lerario, Antonio Marcondes Rainey, William E Auchus, Richard Joseph Hammer, Gary D Else, Tobias |
author_facet | van Rooyen, Desmaré Scheske, Rachel Lerario, Antonio Marcondes Rainey, William E Auchus, Richard Joseph Hammer, Gary D Else, Tobias |
author_sort | van Rooyen, Desmaré |
collection | PubMed |
description | Disclosure: D. van Rooyen: None. R. Scheske: None. A.M. Lerario: None. W.E. Rainey: None. R.J. Auchus: None. G.D. Hammer: None. T. Else: None. Background: Adrenal tumors are very common, with the vast majority being benign adrenocortical adenomas (ACA). Adrenocortical carcinomas (ACC) represent only a very small proportion of adrenal tumors. Distinction between the common ACA and rare ACC relies on invasive and costly protocols which are often inconclusive. Research into the use of steroid biomarkers as a non-invasive alternative diagnostic tool has been the focus of various steroid metabolomics studies. In this study, we aimed to identify serum steroid biomarkers to distinguish ACA from ACC. Methods: This study population was comprised of 103 patient samples, including 45 (31 female) and 58 (40 female) respective samples from ACA (age 32-90) and ACC (age 16-77) patients presenting with disease at the time of sampling. No ACC patients studied had been treated with mitotane. Serum steroid levels (4 sulfates and 25 Δ4 steroids) were measured using liquid-chromatography tandem mass spectrometry (LCMS/MS) with comparisons made between steroid profiles in ACA vs ACC and between males and females within each group (ACA and ACC). Data were analyzed to obtain the geometric means with 95% CIs, and statistical significance was determined using a two-tailed Mann-Whitney test. Results: ACC patients were characterized by significantly elevated levels of pregnenolone-sulfate, 17hydroxypregnenolone-sulfate, 11-deoxycorticosterone, 17hydroxyprogesterone, and androstenedione when compared to ACA patients. In addition, steroid levels differed between male and female samples, with dehydroepiandrosterone-sulfate (p<0.01), androstenediol-3-sulfate (p<0.05), 11deoxycortisol (p<0.0001), cortisol (p<0.05) and testosterone (p<0.01) significantly increased in female ACC patients when compared to male counterparts. Conclusion: Significant differences in plasma steroids were observed in ACC vs ACA patients, with more steroids altered in female patients. Serum steroid profiles, particularly steroid sulfates, might serve as an adjunct, easy to obtain diagnostic tool to differentiate ACA and ACC. Presentation: Friday, June 16, 2023 |
format | Online Article Text |
id | pubmed-10554608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105546082023-10-06 FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) van Rooyen, Desmaré Scheske, Rachel Lerario, Antonio Marcondes Rainey, William E Auchus, Richard Joseph Hammer, Gary D Else, Tobias J Endocr Soc Adrenal (Excluding Mineralocorticoids) Disclosure: D. van Rooyen: None. R. Scheske: None. A.M. Lerario: None. W.E. Rainey: None. R.J. Auchus: None. G.D. Hammer: None. T. Else: None. Background: Adrenal tumors are very common, with the vast majority being benign adrenocortical adenomas (ACA). Adrenocortical carcinomas (ACC) represent only a very small proportion of adrenal tumors. Distinction between the common ACA and rare ACC relies on invasive and costly protocols which are often inconclusive. Research into the use of steroid biomarkers as a non-invasive alternative diagnostic tool has been the focus of various steroid metabolomics studies. In this study, we aimed to identify serum steroid biomarkers to distinguish ACA from ACC. Methods: This study population was comprised of 103 patient samples, including 45 (31 female) and 58 (40 female) respective samples from ACA (age 32-90) and ACC (age 16-77) patients presenting with disease at the time of sampling. No ACC patients studied had been treated with mitotane. Serum steroid levels (4 sulfates and 25 Δ4 steroids) were measured using liquid-chromatography tandem mass spectrometry (LCMS/MS) with comparisons made between steroid profiles in ACA vs ACC and between males and females within each group (ACA and ACC). Data were analyzed to obtain the geometric means with 95% CIs, and statistical significance was determined using a two-tailed Mann-Whitney test. Results: ACC patients were characterized by significantly elevated levels of pregnenolone-sulfate, 17hydroxypregnenolone-sulfate, 11-deoxycorticosterone, 17hydroxyprogesterone, and androstenedione when compared to ACA patients. In addition, steroid levels differed between male and female samples, with dehydroepiandrosterone-sulfate (p<0.01), androstenediol-3-sulfate (p<0.05), 11deoxycortisol (p<0.0001), cortisol (p<0.05) and testosterone (p<0.01) significantly increased in female ACC patients when compared to male counterparts. Conclusion: Significant differences in plasma steroids were observed in ACC vs ACA patients, with more steroids altered in female patients. Serum steroid profiles, particularly steroid sulfates, might serve as an adjunct, easy to obtain diagnostic tool to differentiate ACA and ACC. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554608/ http://dx.doi.org/10.1210/jendso/bvad114.187 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Adrenal (Excluding Mineralocorticoids) van Rooyen, Desmaré Scheske, Rachel Lerario, Antonio Marcondes Rainey, William E Auchus, Richard Joseph Hammer, Gary D Else, Tobias FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) |
title | FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) |
title_full | FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) |
title_fullStr | FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) |
title_full_unstemmed | FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) |
title_short | FRI192 Serum Steroid Biomarkers For The Differential Diagnosis Of Adrenocortical Carcinoma (ACC) And Adrenocortical Adenoma (ACA) |
title_sort | fri192 serum steroid biomarkers for the differential diagnosis of adrenocortical carcinoma (acc) and adrenocortical adenoma (aca) |
topic | Adrenal (Excluding Mineralocorticoids) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554608/ http://dx.doi.org/10.1210/jendso/bvad114.187 |
work_keys_str_mv | AT vanrooyendesmare fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca AT scheskerachel fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca AT lerarioantoniomarcondes fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca AT raineywilliame fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca AT auchusrichardjoseph fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca AT hammergaryd fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca AT elsetobias fri192serumsteroidbiomarkersforthedifferentialdiagnosisofadrenocorticalcarcinomaaccandadrenocorticaladenomaaca |